Novartis signs $8.7bn gene therapy deal

10-04-2018

Novartis signs $8.7bn gene therapy deal

ralwel / iStockphoto.com

Swiss drug maker Novartis is set to strengthen its gene therapy expertise with the $8.7 billion addition of Nasdaq-listed AveXis to its portfolio.


Novartis, mergers and acquisitions, AveXis, healthcare, gene therapy, genetics, biotech

LSIPR